Genotoxicity profiling reveals distinct platform-and cell type-specific effects in therapeutic gene editing for genetic hyperinflammation

Read full text
Authors: Lei Lei, Masako M. Kaufmann, Jessica Lao, Gudrun Thoulass, Sandra Ammann, Hui Xiao, Manuel Rhiel, Viviane Dettmer‐Monaco, Julian Grünewald, Geoffroy Andrieux, Jamal Alzubi, Bret R. Miller
+11 more Kristoffer Weißert, Linda Gräßel, Christoph Schell, Anna L. Illert, J. Keith Joung, Melanie Boerries, Tatjana I. Cornu, Stephan Ehl, Miriam Erlacher, Peter Aichele, Toni Cathomen
Cited by: 3
References: 59

Abstract

Base editors enable precise correction of point mutations without requiring DNA double-strand breaks, yet platform- and cell type-specific genotoxicities remain incompletely characterized. Here, we applied cytosine base editing (CBE) to disrupt a cryptic splice-site mutation in the Unc13d locus of Jinx mice, a model of familial hemophagocytic lymphohistiocytosis type 3 (FHL3). Efficient editing (62%-89%) in fibroblasts, T cells, and hematopoietic stem cells (HSCs) restored Unc13d splicing, reconstituted cytotoxic T cell function, and protected mice from virus-triggered hyperinflammation after transplantation of edited HSCs. Comparative genotoxicity profiling revealed distinct platform- and cell type-specific patterns: hyperactive CBE induced broader off-target activity and more structural variants than CRISPR-Cas9. Although off-target sequence edits persisted, the stability of CBE-induced chromosomal translocations differed between cell types. These findings establish base editing as a therapeutic strategy for a genetically predisposed hyperinflammatory syndrome and underscore the importance of context-specific safety profiling to guide the clinical translation of genome editors.

Fields of Study & Subjects

CRISPR and Genetic Engineering Virus-based gene therapy research RNA regulation and disease

Publication details

Journal / source
Cell stem cell
Publisher
Elsevier BV
Volume
33
Issue
6
Pages
930–944.e5
Publication date
14 May 2026
Language
EN